EHA 2025: A Gateway to Publishing Excellence with The Lancet Haematology
The Lancet Haematology shares on X.
“On your way to EHA2025 Congress in Milan?
Cheryl Lai, Acting Deputy Editor, will be attending and invites you to reach out with enquiries.
Explore our scope, reach & impact, commitment to publishing excellence, & more.”
The Lancet Haematology at EHA 2025: Meet the Editorial Team in Milan
As the global hematology community prepares to gather at the EHA 2025 Congress in Milan, The Lancet Haematology has announced its presence at the event. Cheryl Lai, Acting Deputy Editor, will be attending and welcomes engagement from clinicians, researchers, and authors interested in publishing with the journal.
This is a unique opportunity to connect directly with the editorial team, explore the journal’s high-impact scope, and learn more about its commitment to publishing excellence in hematologic research. Whether you’re submitting original research, reviews, or commentaries, The Lancet Haematology continues to shape the global conversation in cutting-edge hematology.
Explore their mission, global reach, and scientific influence.
Stay updated with Hemostasis Today.
-
Jun 25, 2026, 19:32Javier M. Floren: A Blood Clot Is One of the Most Impressive Examples of Teamwork You’ll Ever See
-
Jun 25, 2026, 19:31Marcin Krzysztof Maniak: Linking Tissue Mechanics to Inflammation in Health and Disease
-
Jun 25, 2026, 19:29Deepak Rawat: A Diagnosis Like Immune Thrombocytopenia Changes Your Perspective
-
Jun 25, 2026, 19:27Srikanth R.: Don’t Ignore Your Health While Chasing Success
-
Jun 25, 2026, 19:27Jamie Nash: Delighted to Receive the BBTS Race and Sanger Award 2026
-
Jun 25, 2026, 15:56Wolfgang Miesbach: Building the Future of Gene Therapy – From Centre Readiness to Long-Term Patient Care
-
Jun 25, 2026, 15:46Amber Yates: Making a Meaningful Difference for People Living with Sickle Cell Disease
-
Jun 25, 2026, 15:43Nancy Cavey: Navigating Disability Benefits for Patients with Immune Thrombocytopenia
-
Jun 25, 2026, 15:28Damon Race: Pursuing Long-Term Expression in Hemophilia A Gene Therapy